secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001104659-24-065609
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics receives EU marketing authorization for LYTENAVA (bevacizumab gamma) for wet AMD
--------------------------------------------------------------------------------

- European Commission granted Marketing Authorization for LYTENAVA (bevacizumab gamma) for wet AMD in the EU.
- LYTENAVA is the first and only authorized ophthalmic formulation of bevacizumab for wet AMD in the EU.
- Approval based on three completed registration trials (NORSE ONE, TWO, THREE) and supporting data.
- Marketing authorization applies automatically to all 27 EU member states plus Iceland, Norway, Liechtenstein.
- Outlook granted an initial 10 years of market exclusivity in the EU for LYTENAVA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924065609/0001104659-24-065609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465924065609/tm2415688d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-065609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer